Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bumetanide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.89 |
| ▸ | USP2 | O75604 | 2/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | HPGD | P15428 | 2/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | CA2 | P00918 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.89 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.89 |
| ▸ | AQP1 | P29972 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bumetanide SCHEMBL29388271 | 0.94 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL27525 | 0.94 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL4425232 | 0.94 | KDM4E (1.00) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL6239781 | 0.93 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL2255359 | 0.93 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL23455698 | 0.93 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL251062 | 0.93 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL28661289 | 0.93 | KDM4E (0.98) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL28549675 | 0.92 | KDM4E (0.96) | KDM4EUSP2ALDH1A1LMNAHPGD | |
| Bumetanide SCHEMBL250621 | 0.92 | KDM4E (0.96) | KDM4EUSP2ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2919769-B1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING FRAGILE X SYNDROME | NEUROCHLORE (FR) | 2020-09-09 | — | — | EP | claimed |
| EP-2523661-B1 | NKCC INHIBITORS FOR THE TREATMENT OF AUTISM | INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) (FR) | 2017-05-10 | — | — | EP | claimed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | claimed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | KDM4E 1504/4885USP2 3752/4885ALDH1A1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.